Last update
5/17/2026
Reviewed By
Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 21 Researches
7.4
USERS' SCORE
Moderately Good
Based on 18 Reviews
7.9
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Calories
15
Total Fat
1.5 g
2%**
Wild Caught Fish Oil Concentrate
1250 mg
†
Total Omega-3 Fatty Acids as TG
1055 mg
†
EPA (Eicosapentaenoic Acid)
690 mg
†
DHA (Docosahexaenoic Acid)
310 mg
†
Other Omega-3 Fatty Acids
55 mg
†
Top Medical Research Studies
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
8
We explored how eicosapentaenoic acid (EPA), a key component of omega-3 fatty acids, influences cardiovascular health by analyzing the Vitamin D and Omega-3 Trial (VITAL). This large, randomized controlled trial involved 25,871 older adults in the U.S., with a median follow-up of 5.3 years to assess the effects of daily supplementation.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Read More
7
Omega-3s Reduce Heart Disease Risk
We explored how levels of marine omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), impact the risk of cardiovascular (CV) events and overall mortality in patients undergoing maintenance hemodialysis. This study involved a robust, prospective multicenter cohort design with five years of follow-up, focusing on how different levels of these beneficial fatty acids correlate with heart health.
Our findings revealed that patients with lower levels of these fatty acids faced a significantly higher risk of cardiovascular events, as well as an increase in peripheral arterial disease and all-cause mortality. Specifically, those in the lowest group of marine n-3 PUFA levels had a markedly elevated risk compared to those with higher levels.
This suggests that incorporating more sources of EPA and DHA into the diet or through supplements could be a valuable strategy for improving heart health among patients receiving hemodialysis. This study contributes to the growing body of evidence supporting the heart-protective benefits of omega-3 fatty acids, particularly in high-risk populations.
Our findings revealed that patients with lower levels of these fatty acids faced a significantly higher risk of cardiovascular events, as well as an increase in peripheral arterial disease and all-cause mortality. Specifically, those in the lowest group of marine n-3 PUFA levels had a markedly elevated risk compared to those with higher levels.
This suggests that incorporating more sources of EPA and DHA into the diet or through supplements could be a valuable strategy for improving heart health among patients receiving hemodialysis. This study contributes to the growing body of evidence supporting the heart-protective benefits of omega-3 fatty acids, particularly in high-risk populations.
Read More
Most Useful Reviews
7.5
Supports cardiovascular health
327 people found this helpful
My choice! As a nutritionist, I am always studying, and this Omega is highly recommended by reputable functional medicine doctors. I suggest it to my clients and take it myself. It has a decent composition and provides excellent results in supporting cardiovascular health. A tip: to prevent omega-3 from oxidising in the body, take it alongside vitamin E. To check the quality of omega-3, cut the capsule and sniff or taste its contents; it should be fresh and pleasant without any rancid aftertaste. I’ve tested it and the quality is superb! Fresh fish oil inside! I highly recommend this manufacturer and hope my review helps you. Wishing you and your family good health.
Read More
9
Improved cardiovascular health
1 people found this helpful
Since I started taking one pill each day, I've seen significant improvement in my joint issues and my cardiovascular health.
Read More
9
Immune system health
Excellent! This Omega-3 has the highest concentration per capsule, contributing to the health of both the cardiovascular and immune systems.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 21 Researches
7.4
- All Researches
9
Icosapent ethyl reduces cardiovascular risks
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
Read More
9
We explored the effectiveness of eicosapentaenoic acid (EPA), a type of omega-3 polyunsaturated fatty acid (PUFA), in managing heart failure. By analyzing data from multiple randomized controlled trials, we aimed to identify the best doses and treatment durations for EPA supplementation.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
The findings from our network meta-analysis included 14 studies with nearly 9,000 participants, primarily older adults with heart failure. We discovered that high doses of omega-3 PUFAs, specifically between 2000 and 4000 mg per day for at least one year, significantly improved heart function. This was measured by an increase in the left ventricular ejection fraction and peak oxygen consumption.
However, lower doses and shorter supplementation periods did not yield similar benefits. It's worth noting that EPA supplementation did not increase the risk of adverse events, as dropout rates and overall mortality were comparable to control groups.
Our study suggests that long-term, high-dose omega-3 supplementation shows promise for enhancing heart function in individuals with heart failure. Nonetheless, we believe that more in-depth clinical trials are necessary to confirm these results and ensure the findings are robust and reliable.
Read More
9
We delved into how Antarctic krill oil, rich in eicosapentaenoic acid (EPA), can influence cardiovascular health, specifically in the context of obesity. Our focus centered on its effects in mice fed a high-fat diet, which typically leads to increased cholesterol levels and oxidative stress—conditions that can heighten cardiovascular disease risk.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Through our research methods, including molecular docking and analysis of liver histology, we discovered that Antarctic krill oil appears to play a beneficial role in combating these adverse effects. We observed that the oil reduced oxidative stress and fat accumulation in these obese mice. This was associated with improved metabolic parameters that contribute to heart health, primarily through its action on molecules involved in cholesterol metabolism.
Notably, we found that krill oil helped lower the levels of harmful low-density lipoprotein cholesterol and activated pathways that support good cholesterol management in the body. These findings suggest that incorporating Antarctic krill oil, with its high EPA content, might be a promising strategy for addressing obesity-related cardiovascular issues.
Overall, our study points to the potential of eicosapentaenoic acid from krill oil as a natural approach to improving heart health, particularly for those struggling with obesity and its challenges.
Read More
9
We explored the impact of eicosapentaenoic acid (EPA), a nutrient known for its heart benefits, on diabetic cardiomyopathy (DC), a condition leading to heart failure. Our study focused on diabetic mice and revealed that EPA plays a protective role against DC, particularly by reducing harmful M1-polarized macrophages in the heart.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
In our experiments, we found that EPA not only reduces cardiomyocyte injury caused by M1-polarized macrophages but also encourages a shift in macrophages' behavior from M1 to a protective Mox state—not M2. This shift is crucial because Mox macrophages help mitigate the damage inflicted by their M1 counterparts.
We identified heme oxygenase 1 (HO-1) as a key player in maintaining the Mox phenotype. EPA promotes HO-1, which helps curb macrophage M1 polarization and the resulting cardiomyocyte injury. Interestingly, our findings also showed that EPA fosters this protective Mox polarization in monocyte-derived macrophages from diabetic patients, suggesting a broader application for this treatment strategy.
Overall, our study highlights the potential of EPA as a novel approach to combat diabetic cardiomyopathy, emphasizing the importance of macrophage Mox polarization in maintaining heart health in diabetes.
Read More
8
We explored how eicosapentaenoic acid (EPA), a key component of omega-3 fatty acids, influences cardiovascular health by analyzing the Vitamin D and Omega-3 Trial (VITAL). This large, randomized controlled trial involved 25,871 older adults in the U.S., with a median follow-up of 5.3 years to assess the effects of daily supplementation.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 18 Reviews
7.9
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Supports cardiovascular health
327 people found this helpful
My choice! As a nutritionist, I am always studying, and this Omega is highly recommended by reputable functional medicine doctors. I suggest it to my clients and take it myself. It has a decent composition and provides excellent results in supporting cardiovascular health. A tip: to prevent omega-3 from oxidising in the body, take it alongside vitamin E. To check the quality of omega-3, cut the capsule and sniff or taste its contents; it should be fresh and pleasant without any rancid aftertaste. I’ve tested it and the quality is superb! Fresh fish oil inside! I highly recommend this manufacturer and hope my review helps you. Wishing you and your family good health.
Read More
9
Improved cardiovascular health
1 people found this helpful
Since I started taking one pill each day, I've seen significant improvement in my joint issues and my cardiovascular health.
Read More
9
Immune system health
Excellent! This Omega-3 has the highest concentration per capsule, contributing to the health of both the cardiovascular and immune systems.
Read More
8
Effective for inflammation
This fish oil is a repeated purchase for me. It boasts quality ingredients and has effectively mitigated inflammation while protecting my cardiovascular system over many years.
Read More
7.5
Reduces cardiovascular risk
2 people found this helpful
I confidently bought 180 tablets this time, which made for a large product box. I've taken omega oils, and studies show they can reduce cardiovascular risk by up to 25%.
Read More
Frequently Asked Questions
7.5
Good for cardiovascular health
1 people found this helpful
The best fish oil I've found. It came well-packaged and clean, and I've noticed benefits for my cardiovascular health after a month of taking it without discomfort. High dose, one daily pill is easy enough to manage.
8
Effective for inflammation
This fish oil is a repeated purchase for me. It boasts quality ingredients and has effectively mitigated inflammation while protecting my cardiovascular system over many years.
7.5
Constant consumption benefits
This brand of Omega 3 is one I continuously order. I diligently take it to preserve my cardiovascular system and overall health. The capsule composition is excellent, requiring only one a day, and is sourced from wild Alaskan pollock with no aftertaste.
9
Improved cardiovascular health
1 people found this helpful
Since I started taking one pill each day, I've seen significant improvement in my joint issues and my cardiovascular health.
7.5
Supports cardiovascular health
327 people found this helpful
My choice! As a nutritionist, I am always studying, and this Omega is highly recommended by reputable functional medicine doctors. I suggest it to my clients and take it myself. It has a decent composition and provides excellent results in supporting cardiovascular health. A tip: to prevent omega-3 from oxidising in the body, take it alongside vitamin E. To check the quality of omega-3, cut the capsule and sniff or taste its contents; it should be fresh and pleasant without any rancid aftertaste. I’ve tested it and the quality is superb! Fresh fish oil inside! I highly recommend this manufacturer and hope my review helps you. Wishing you and your family good health.
8
We explored how eicosapentaenoic acid (EPA), a key component of omega-3 fatty acids, influences cardiovascular health by analyzing the Vitamin D and Omega-3 Trial (VITAL). This large, randomized controlled trial involved 25,871 older adults in the U.S., with a median follow-up of 5.3 years to assess the effects of daily supplementation.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
Initially, the results seemed non-significant for major cardiovascular events. However, our Bayesian analysis, which incorporated previous research, showed more positive outcomes. We observed that EPA supplementation could significantly reduce the risk of coronary events, such as total coronary heart disease (CHD) and myocardial infarction, while it didn’t seem to impact stroke rates.
These findings enhance our understanding of omega-3 supplements in preventing heart-related issues, emphasizing their potential as a primary preventative measure against coronary diseases.
7
Omega-3s Reduce Heart Disease Risk
We explored how levels of marine omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), impact the risk of cardiovascular (CV) events and overall mortality in patients undergoing maintenance hemodialysis. This study involved a robust, prospective multicenter cohort design with five years of follow-up, focusing on how different levels of these beneficial fatty acids correlate with heart health.
Our findings revealed that patients with lower levels of these fatty acids faced a significantly higher risk of cardiovascular events, as well as an increase in peripheral arterial disease and all-cause mortality. Specifically, those in the lowest group of marine n-3 PUFA levels had a markedly elevated risk compared to those with higher levels.
This suggests that incorporating more sources of EPA and DHA into the diet or through supplements could be a valuable strategy for improving heart health among patients receiving hemodialysis. This study contributes to the growing body of evidence supporting the heart-protective benefits of omega-3 fatty acids, particularly in high-risk populations.
Our findings revealed that patients with lower levels of these fatty acids faced a significantly higher risk of cardiovascular events, as well as an increase in peripheral arterial disease and all-cause mortality. Specifically, those in the lowest group of marine n-3 PUFA levels had a markedly elevated risk compared to those with higher levels.
This suggests that incorporating more sources of EPA and DHA into the diet or through supplements could be a valuable strategy for improving heart health among patients receiving hemodialysis. This study contributes to the growing body of evidence supporting the heart-protective benefits of omega-3 fatty acids, particularly in high-risk populations.
8
Eicosapentaenoic acid improves endothelial function
We aimed to explore how eicosapentaenoic acid (EPA) influences cardiovascular health, specifically its effects on endothelial function in patients dealing with coronary artery disease (CAD) while on statin therapy. Our study involved 150 patients who were receiving statins to lower their cholesterol levels and who had LDL cholesterol levels below 100 mg/dL.
By measuring serum omega-3 fatty acid levels, we assessed endothelial function using a technique called flow-mediated dilation (FMD) of the brachial artery. This method helps understand how well blood vessels are responding to blood flow. Among these patients, we identified 65 individuals with impaired FMD (less than 6%) who also had low EPA/arachidonic acid ratios. We then provided them with EPA therapy and reassessed their endothelial function after three months.
Our analysis revealed that higher levels of docosahexaenoic acid (DHA) and combined EPA plus DHA were linked to better FMD outcomes. Notably, after EPA treatment, the FMD percentage improved significantly from 3.7% to 4.1% among those with low EPA/AA ratios. This improvement was even more pronounced in patients who exhibited both low EPA/AA levels and high triglyceride levels.
In summary, our findings indicate that serum omega-3 fatty acids are connected to endothelial dysfunction in CAD patients on statin therapy. Moreover, EPA therapy shows promise in enhancing endothelial function, particularly in a subset of patients with specific biochemical profiles.
By measuring serum omega-3 fatty acid levels, we assessed endothelial function using a technique called flow-mediated dilation (FMD) of the brachial artery. This method helps understand how well blood vessels are responding to blood flow. Among these patients, we identified 65 individuals with impaired FMD (less than 6%) who also had low EPA/arachidonic acid ratios. We then provided them with EPA therapy and reassessed their endothelial function after three months.
Our analysis revealed that higher levels of docosahexaenoic acid (DHA) and combined EPA plus DHA were linked to better FMD outcomes. Notably, after EPA treatment, the FMD percentage improved significantly from 3.7% to 4.1% among those with low EPA/AA ratios. This improvement was even more pronounced in patients who exhibited both low EPA/AA levels and high triglyceride levels.
In summary, our findings indicate that serum omega-3 fatty acids are connected to endothelial dysfunction in CAD patients on statin therapy. Moreover, EPA therapy shows promise in enhancing endothelial function, particularly in a subset of patients with specific biochemical profiles.
9
Icosapent ethyl reduces cardiovascular risks
We explored the effectiveness of icosapent ethyl, a form of eicosapentaenoic acid, in reducing cardiovascular events among statin-treated patients who had high cardiovascular risk and controlled cholesterol levels.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
In this analysis of the REDUCE-IT trial, 8,175 patients with elevated triglycerides were observed. These patients were divided based on their low-density lipoprotein cholesterol (LDL-C) levels before treatment. We found that, overall, icosapent ethyl lead to significant reductions in major cardiovascular events, regardless of whether LDL-C was less than or greater than 55 mg/dL.
Specifically, those with LDL-C levels below 55 mg/dL experienced a drop in serious cardiovascular issues from 22.8% to 16.2% when treated with icosapent ethyl. Likewise, patients with LDL-C levels at or above 55 mg/dL showed improvements, with cardiovascular event rates declining from 21.9% to 17.4%. These results indicate that this treatment could be beneficial for patients who maintain good LDL-C levels while having high triglycerides.
Overall, we have strong evidence that icosapent ethyl effectively reduces cardiovascular risks in high-risk patients, which is great news for those looking for additional treatment options alongside statins.
References
- Hamaya R, Cook NR, Sesso HD, Buring JE, Manson JE. A Bayesian Analysis of the VITAL Trial: Effects of Omega-3 Fatty Acid Supplementation on Cardiovascular Events. Am J Clin Nutr. 2025. 10.1016/j.ajcnut.2025.02.028
- Liboriussen C, Nygaard L, Jensen JD, Schmidt EB, Glerup RI, et al. Low Plasma Marine N-3 Polyunsaturated Fatty Acids are Associated with Increased Risk of Cardiovascular Events in Patients Treated with Maintenance Hemodialysis. J Ren Nutr. 2025. 10.1053/j.jrn.2025.02.001
- Yunoki K, Matsumi H, Miyoshi T, Kubo M, Hata Y, et al. Clinical Significance of Serum Omega-3 Fatty Acids on Endothelial Function in Patients with Coronary Artery Disease Under Statin Therapy. J Cardiovasc Dev Dis. 2025;12. 10.3390/jcdd12020060
- Aggarwal R, Bhatt DL, Steg PG, Miller M, Brinton EA, et al. Cardiovascular Outcomes With Icosapent Ethyl by Baseline Low-Density Lipoprotein Cholesterol: A Secondary Analysis of the REDUCE-IT Randomized Trial. J Am Heart Assoc. 2025;14:e038656. 10.1161/JAHA.124.038656
- Tseng PT, Zeng BY, Hsu CW, Liang CS, Stubbs B, et al. The Optimal Dosage and Duration of ω-3 PUFA Supplementation in Heart Failure Management: Evidence from a Network Meta-Analysis. Adv Nutr. 2025;16:100366. 10.1016/j.advnut.2025.100366
- Patil T, Gregory M, Savona N, Jarmukli N, Leonard CE. Evaluating the Real-World Safety of Icosapent Ethyl Versus Omega-3 Polyunsaturated Fatty Acid in Nationwide US Veterans Cohort: Examining Atrial Fibrillation and Bleeding Endpoints. Clin Drug Investig. 2025;45:69. 10.1007/s40261-024-01417-4
- Kim JY, Kong SYJ, Jung E, Cho YS. Omega-3 Fatty Acids as Potential Predictors of Sudden Cardiac Death and Cardiovascular Mortality: A Systematic Review and Meta-Analysis. J Clin Med. 2024;14. 10.3390/jcm14010026
- Lamon-Fava S. Associations between omega-3 fatty acid-derived lipid mediators and markers of inflammation in older subjects with low-grade chronic inflammation. Prostaglandins Other Lipid Mediat. 2025;176:106948. 10.1016/j.prostaglandins.2025.106948
- Fukuda T, Nakajima T, Hasegawa T, Amano H, Arikawa T, et al. Relationship Between Serum ω-3 Polyunsaturated Fatty Acid Concentration and Fatty Acid Fraction of Epicardial Adipose Tissue in Patients With Cardiovascular Disease. Cureus. 2024;16:e73417. 10.7759/cureus.73417
- O'Keefe EL, O'Keefe JH, Abuissa H, Metzinger M, Murray E, et al. Omega-3 and Risk of atrial fibrillation: Vagally-mediated double-edged sword. Prog Cardiovasc Dis. 2024. 10.1016/j.pcad.2024.11.003
- Choi JH, Park SE, Kim S. Antarctic Krill Oil Supplementation Attenuates Hypercholesterolemia, Fatty Liver, and Oxidative Stress in Diet-Induced Obese Mice. Nutrients. 2024;16. 10.3390/nu16213614
- So J, Yao JH, Magadmi R, Matthan NR, Lamon-Fava S. Sex differences in lipid mediators derived from omega-3 fatty acids in older individuals with low-grade chronic inflammation. Prostaglandins Leukot Essent Fatty Acids. 2024;203:102655. 10.1016/j.plefa.2024.102655
- Li J, Nan W, Huang X, Meng H, Wang S, et al. Eicosapentaenoic acid induces macrophage Mox polarization to prevent diabetic cardiomyopathy. EMBO Rep. 2024;25:5507. 10.1038/s44319-024-00271-x
- Choi GY, Calder PC. The differential effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors: an updated systematic review of randomized controlled trials. Front Nutr. 2024;11:1423228. 10.3389/fnut.2024.1423228
- Follonier C, Rabassa G, Branca M, Carballo D, Koskinas K, et al. Eligibility for marine omega-3 fatty acid supplementation after acute coronary syndromes. Atheroscler Plus. 2024;58:1. 10.1016/j.athplu.2024.09.002
- Koutsaliaris IK, Pantazi D, Tsouka AN, Argyropoulou O, Tellis CC, et al. Differential Effect of Omega-3 Fatty Acids on Platelet Inhibition by Antiplatelet Drugs In Vitro. Int J Mol Sci. 2024;25. 10.3390/ijms251810136
- Ren Y, Chen B, Zhang H, Xu S. A cohort study reveals shared and distinct serum metabolic biomarkers for major adverse cardiovascular events in middle-aged and older adults. Geroscience. 2025. 10.1007/s11357-025-01544-6
- Arghavani H, Bilodeau JF, Rudkowska I. Association Between Circulating Fatty Acids and Blood Pressure: A Review. Curr Nutr Rep. 2025;14:15. 10.1007/s13668-024-00602-3
- Li J, Guo J, Yuen M, Yuen H, Peng Q. The comparative effects of ω-7 fatty acid-rich sea buckthorn oil and ω-3 fatty acid-rich DHA algal oil on improving high-fat diet-induced hyperlipidemia. Food Funct. 2025;16:1241. 10.1039/d4fo04961f
- Berkowitz L, Echeverría G, Salazar C, Faúndez C, Coe CL, et al. Lipidomic Signature of Healthy Diet Adherence and Its Association with Cardiometabolic Risk in American Adults. Nutrients. 2024;16. 10.3390/nu16233995
- Shi F, Chowdhury R, Sofianopoulou E, Koulman A, Sun L, et al. Association of circulating fatty acids with cardiovascular disease risk: analysis of individual-level data in three large prospective cohorts and updated meta-analysis. Eur J Prev Cardiol. 2025;32:233. 10.1093/eurjpc/zwae315
